Company News

Term: Company News

  • July 27, 2017
    NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the second quarter of 2017. Total revenues in the quarter were $912 million, a 21 percent increase compared to the same period in 2016. Second quarter revenue reflected a benefit of approximately $35 million due to favorable timing of orders compared to our prior forecast. The negative impact of foreign currency on total revenue year-over-year was 2 percent or $12more...
  • July 11, 2017
    NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the second quarter 2017 on Thursday, July 27, 2017 before the US financial markets open. Following the release of the financial results, Alexion management will conduct a conference call and audio webcast to discuss the second quarter 2017 financial results and strategic update on Thursday, July 27, 2017, at 10:00 a.m. Eastern Timemore...
  • July 5, 2017
    NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced that it has reached a national funding agreement with the National Institute for Health and Care Excellence (NICE) and the National Health Service (NHS) England based on a Managed Access Agreement (MAA), which provides access to Strensiq® (asfotase alfa) for patients in England with pediatric-onset hypophosphatasia (HPP), regardless of their current age. The funding agreement was announced today in a positive final evaluationmore...
  • June 23, 2017
    NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to extend the current therapeutic indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive. The final decision from the Europeanmore...
  • June 13, 2017
    NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Paul J. Clancy, a seasoned financial executive with 30 years of experience, will join the company on July 10, 2017 and will assume the role of Chief Financial Officer (CFO) effective July 31, 2017. For the past 16 years, Mr. Clancy has been employed by Biogen where he has served as CFO for the last ten years. Prior to Biogen, Mr. Clancy spent 13 years with PepsiCo in variousmore...
  • June 1, 2017
    NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) today announced key additions to its executive leadership team effective June 5, 2017. Reporting to Chief Executive Officer, Ludwig Hantson will be: John Orloff, M.D., Executive Vice President, Head of Research & Development, Anne-Marie Law, Executive Vice President, Chief Human Resources Officer, and Indrani Lall Franchini, J.D., Executive Vice President, Chief Compliance Officer. “I ammore...
  • May 30, 2017
    NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that management will present at two upcoming investor conferences: Goldman Sachs 38th Annual Global Healthcare Conference in Rancho Palos Verdes on Tuesday, June 13, 2017 at 11:20 a.m., PT (2:20 p.m., ET). William Blair 37th Annual Growth Stock Conference in Chicago on Wednesday, June 14, 2017 at 11:20 a.m., CT (12:20 p.m., ET). An audio webcast of eachmore...
  • May 23, 2017
    NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced the following changes to its executive leadership team: Brian Goff is joining Alexion as Chief Commercial Officer, effective June 1, 2017. Mr. Goff is a veteran biopharmaceutical executive with more than 25 years of experience at companies including Neurovance, Inc., Baxalta, Inc., Baxter, Novartis and Johnson & Johnson. Mr. Goff will lead all commercialmore...
  • May 16, 2017
    SAN DIEGO & NEW HAVEN, Conn.--(BUSINESS WIRE)--The Rady Children’s Institute for Genomic Medicine (RCIGM) and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced a strategic partnership to accelerate the diagnosis of critically-ill newborns with rare genetic disorders. The collaboration combines the Institute’s genomic research expertise with Alexion data science and bioinformatics capabilities to advance precision medicine for infants in an intensive care setting.“Diagnosing acutely ill babies is a race against the clock, so it’smore...
  • May 15, 2017
    NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that researchers presented data showing that the rapid benefits of Strensiq® (asfotase alfa) achieved in adolescents and adults (ages 13-66 years at study entry) with hypophosphatasia (HPP) within the first 6 months were sustained through 5 years of treatment.1 These are the final data from the extension phase of a randomized, open-label, dose-ranging Phase 2 trial of Strensiq and theymore...